Lotus Pharmaceutical Co Ltd
TWSE:1795

Watchlist Manager
Lotus Pharmaceutical Co Ltd Logo
Lotus Pharmaceutical Co Ltd
TWSE:1795
Watchlist
Price: 281.5 TWD -1.4% Market Closed
Market Cap: 74.7B TWD
Have any thoughts about
Lotus Pharmaceutical Co Ltd?
Write Note

Lotus Pharmaceutical Co Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lotus Pharmaceutical Co Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Lotus Pharmaceutical Co Ltd
TWSE:1795
Note Receivable
NT$168.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Y
YungShin Global Holding Corp
TWSE:3705
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Formosa Laboratories Inc
TWSE:4746
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ScinoPharm Taiwan Ltd
TWSE:1789
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
SCI Pharmtech Inc
TWSE:4119
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Standard Chem & Pharm Co Ltd
TWSE:1720
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Lotus Pharmaceutical Co Ltd
Glance View

Market Cap
74.4B TWD
Industry
Pharmaceuticals

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of generic pharmaceutical products; and the provision of consulting services. The company is headquartered in Taipei City, Taipei. The company went IPO on 2004-12-13. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The firm is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The firm mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.

Intrinsic Value
362.33 TWD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Lotus Pharmaceutical Co Ltd's Note Receivable?
Note Receivable
168.9m TWD

Based on the financial report for Jun 30, 2024, Lotus Pharmaceutical Co Ltd's Note Receivable amounts to 168.9m TWD.

Back to Top